Radiofrequency heat‑enhanced direct intratumoral chemotherapy for prostate cancer

Wu,Xia; Zhang,Feng; Hu,Peng; Chen,Lumin; Han,Guocan; Bai,Weixian; Luo,Jingfeng; Chen,Ran; Zhou,Yurong; Sun,Jihong; Yang,Xiaoming

doi:10.3892/ol.2017.7145

Radiofrequency heat‑enhanced direct intratumoral chemotherapy for prostate cancer

Authors:
- Xia Wu
- Feng Zhang
- Peng Hu
- Lumin Chen
- Guocan Han
- Weixian Bai
- Jingfeng Luo
- Ran Chen
- Yurong Zhou
- Jihong Sun
- Xiaoming Yang
View Affiliations

Affiliations: Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University College of Medicine and Sir Run Run Shaw Institute of Clinical Medicine of Zhejiang University, Hangzhou, Zhejiang 310016, P.R. China, Image‑Guided Bio‑Molecular Intervention Research and Section of Vascular and Interventional Radiology, Department of Radiology, University of Washington School of Medicine, Seattle, WA 98195, USA, Department of Diagnostic Ultrasound and Echocardiography, Sir Run Run Shaw Hospital, Zhejiang University College of Medicine and Sir Run Run Shaw Institute of Clinical Medicine of Zhejiang University, Hangzhou, Zhejiang 310016, P.R. China
Published online on: October 6, 2017 https://doi.org/10.3892/ol.2017.7145
Pages: 7250-7256
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A novel, minimally invasive interventional technique, radiofrequency heat (RFH), has been suggested to improve the efficacy of chemotherapy for solid organ tumors. However, the treatment for prostate cancer has not been completely characterized. The aim of the present study was to investigate the in vitro and in vivo efficiency of chemotherapy in combination with RFH for the treatment of prostate cancer. The following four treatment groups were included: i) No treatment (control); ii) RFH‑only; iii) chemotherapy (docetaxel)‑only; and iv) combination therapy of docetaxel and RFH in human prostate cancer (HPC) cell lines and mice with HPC xenografts. In the in vitro experiments, a heating guidewire was attached under the bottom of the last chamber of the four‑chamber cell culture slide, and was then connected to a radiofrequency (RF) generator. In the in vivo experiments, a tumor model was generated by subcutaneously injecting human prostate cancer cells into 24 male nu/nu mice. RFH was conducted by inserting the 0.022‑inch heating‑guidewire into the tumor. The follow‑up magnetic resonance imaging demonstrated a significant reduction in the average tumor size in animals treated with combination therapy compared with those receiving RFH‑only and chemotherapy‑only. The number of apoptotic cells and the average apoptotic index of the combination therapy group were significantly higher compared with those of the other three treatment groups. In conclusion, the results of the present study suggested that RFH is able to increase the therapeutic efficiency of docetaxel in prostate cancer, and this study serves as a foundation for the future development of an interventional molecular image‑guided local treatment strategy for prostate cancer that integrates RF technology, interventional oncology and direct intratumoral chemotherapy, as a replacement for systemic chemotherapy.

View Figures

View References

1	Wolff RF, Ryder S, Bossi A, Briganti A, Crook J, Henry A, Karnes J, Potters L, de Reijke T, Stone N, et al: A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer. Eur J Cancer. 51:2345–2367. 2015. View Article : Google Scholar : PubMed/NCBI
2	Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, et al: Prevention and early detection of prostate cancer. Lancet Oncol. 15:e484–e492. 2014. View Article : Google Scholar : PubMed/NCBI
3	Litwin MS and Tan HJ: The diagnosis and treatment of prostate cancer: A reviwe. JAMA. 317:2532–2542. 2017. View Article : Google Scholar : PubMed/NCBI
4	Polascik TJ, Mayes JM, Sun L, Madden JF, Moul JW and Mouraviev V: Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: Implications for unilateral ablative therapy. Prostate. 68:1380–1386. 2008. View Article : Google Scholar : PubMed/NCBI
5	Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J and Hugosson J: National prostate cancer register (NPCR) of Sweden: Outcomes in localized prostate cancer: National prostate cancer register of Sweden follow-up study. J Natl Cancer Inst. 102:950–958. 2010. View Article : Google Scholar : PubMed/NCBI
6	Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, et al: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 65:467–479. 2014. View Article : Google Scholar : PubMed/NCBI
7	Wu X, Zhang F, Chen R, Zheng W and Yang X: Recent advances in imaging-guided interventions for prostate cancers. Cancer Lett. 349:114–119. 2014. View Article : Google Scholar : PubMed/NCBI
8	Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, et al: Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 324:1457–1461. 2009. View Article : Google Scholar : PubMed/NCBI
9	Coleman JA and Scardino PT: Targeted prostate cancer ablation: Energy options. Curr Opin Urol. 23:123–128. 2013. View Article : Google Scholar : PubMed/NCBI
10	Zhang F, Le T, Wu X, Wang H, Zhang T, Meng Y, Wei B, Soriano SS, Willis P, Kolokythas O and Yang X: Intrabiliary RF heat-enhanced local chemotherapy of a cholangiocarcinoma cell line: Monitoring with dual-modality imaging-preclinical study. Radiology. 270:400–408. 2014. View Article : Google Scholar : PubMed/NCBI
11	Zhang T, Zhang F, Meng Y, Wang H, Le T, Wei B, Lee D, Willis P, Shen B and Yang X: Diffusion-weighted MRI monitoring of pancreatic cancer response to radiofrequency heat-enhanced intratumor chemotherapy. NMR Biomed. 26:1762–1267. 2013. View Article : Google Scholar : PubMed/NCBI
12	Owusu RA, Abern MR and Inman BA: Hyperthermia as adjunct to intravesical chemotherapy for bladder cancer. Biomed Res Int. 2013:2623132013. View Article : Google Scholar : PubMed/NCBI
13	Neto Serpa A, Tobias-Machado M, Kaliks R, Wroclawski ML, Pompeo AC and Del Giglio A: Ten years of docetaxel-based therapies in prostate adenocarcinoma: A systematic review and meta-analysis of 2244 patients in 12 randomized cliniical trials. Clin Genitourin Cancer. 9:115–123. 2011. View Article : Google Scholar : PubMed/NCBI
14	Zhou Y, Han G, Wang Y, Hu X, Li Z, Chen L, Bai W, Luo J, Zhang Y, Sun J and Yang X: Radiofrequency heat-enhanced chemotherapy for breast cancer: Towards interventional molecular image-guided chemotherapy. Theranostics. 4:1145–1152. 2014. View Article : Google Scholar : PubMed/NCBI
15	Morikawa Y, Koike H, Sekine Y, Matsui H, Shibata Y, Ito K and Suzuki K: Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation. Biochem Biophys Res Commun. 419:584–589. 2012. View Article : Google Scholar : PubMed/NCBI
16	Williams JF, Muenchen HJ, Kamradt JM, Korenchuk S and Pienta KJ: Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: An experimental study. Prostate. 44:275–278. 2000. View Article : Google Scholar : PubMed/NCBI
17	Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, Åström L, Franzen L, Marttila T, Seke M, Taalikka M and Ginman C: SPCG-13: Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: A preplanned safety report of the SPCG-13 trial. Prostate Cancer Prostatic Dis. 15:303–307. 2012. View Article : Google Scholar : PubMed/NCBI
18	Johannsen M, Thiesen B, Wust P and Jordan A: Magnetic nanoparticle hyperthermia for prostate cancer. Int J Hyperthemia. 26:790–795. 2010. View Article : Google Scholar
19	Kim KW, Chow O, Parikh K, Blank S, Jibara G, Kadri H, Labow DM and Hiotis SP: Peritoneal carcinomatosis in patients with gastric cancer, and the role for surgical resection, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy. Am J Surg. 207:78–83. 2014. View Article : Google Scholar : PubMed/NCBI
20	Ahmed M, Brace CL, Lee FT Jr and Goldberg SN: Principles of and advances in percutaneous ablation. Radiology. 258:351–369. 2011. View Article : Google Scholar : PubMed/NCBI
21	Madio DP, van Gelderen P, DesPres D, Olson AW, de Zwart JA, Fawcett TW, Holbrook NJ, Mandel M and Moonen CT: On the feasibility of MRI-guided focused ultrasound for local induction of gene expression. J Magn Reson Imaging. 8:101–104. 1998. View Article : Google Scholar : PubMed/NCBI
22	Wei Z, Ye X, Yang X, Zheng A, Huang G, Li W, Ni X, Wang J and Han X: Microwave ablation in combination with chemotherapy for the treatment of advanced non-small cell lung cancer. Cardiovasc Intervent Radiol. 38:135–142. 2015. View Article : Google Scholar : PubMed/NCBI